ADAMTS4 mediates LPS-induced cardiac injury and myocardial fibrosis through proteolytic cleavage of TSP1

Abstract

Septic cardiomyopathy is characterized by acute cardiac dysfunction, while sustained inflammatory and extracellular matrix remodeling may contribute to subsequent myocardial fibrosis and impaired cardiac recovery. A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) has been linked to fibrotic remodelling, but its role in septic cardiac injury remains unclear. Here, we show that Adamts4 is upregulated in LPS-induced septic mouse hearts and is predominantly induced in cardiac fibroblasts. Using three fibroblast-lineage Adamts4 knockout models, we demonstrate that Adamts4 deletion attenuates LPS-induced cardiac dysfunction, inflammation and fibrosis, whereas Tcf21-lineage fibroblast Adamts4 overexpression aggravates these changes. Mechanistically, ADAMTS4 interacts with thrombospondin-1 (TSP1) and promotes its catalytic activity-dependent proteolytic processing. The 236–246 amino acid region of TSP1 is required for fragment generation and fibroblast activation. TSP1 processing further activates TGF-β/Smad and NF-κB signalling, promoting myofibroblast activation and extracellular matrix deposition. These findings identify ADAMTS4 as a fibroblast-centred driver of septic cardiac fibrosis and suggest that targeting the ADAMTS4-TSP1 axis may offer therapeutic potential for septic cardiomyopathy.

Keywords

ADAMTS4 / cardiac fibrosis / cardiac function / inflammation / TSP1

References

[1] O'Brien JM Jr, Ali NA, Aberegg SK, et al. Sepsis. Am J Med. 2007; 120(12): 1012-1022.

[2] Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021; 47(11): 1181-1247.

[3] Zhao Y, Xu Z, Lin J, et al. Current status of septic cardiomyopathy: basic science and clinical progress. Front Pharmacol. 2020; 11: 210.

[4] Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021; 18(6): 424-434.

[5] Beesley SJ, Weber G, Sarge T, et al. Septic cardiomyopathy. Crit Care Med. 2018; 46(4): 625-634.

[6] Lindner D, Hilfiker-Kleiner D, Kramer F, Tschope C. Inflammation-induced cardiac fibroblast activation in heart failure — pathophysiology and therapeutic implications. Cell Tissue Res. 2021; 384(3): 571-584.

[7] Angeli E, Jordan M, Otto M, et al. The role of fibrosis in cardiomyopathies: an opportunity to develop novel biomarkers of disease activity. Matrix Biol. 2024; 128: 65-78.

[8] Fushimi K, Troeberg L, Nakamura H, et al. Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem. 2008; 283(11): 6706-6716.

[9] de Groot R, Folgado PB, Yamamoto K, et al. Cleavage of Cartilage Oligomeric Matrix Protein (COMP) by Adamts4 generates a neoepitope associated with osteoarthritis and other forms of degenerative joint disease. Matrix Biol. 2025; 135: 106-124.

[10] Zhai W, Yang W, Ge J, et al. Adamts4 exacerbates lung cancer progression via regulating c-Myc protein stability and activating MAPK signaling pathway. Biol Direct. 2024; 19(1): 94.

[11] Boyd DF, Allen EK, Randolph AG, et al. Exuberant fibroblast activity compromises lung function via ADAMTS4. Nature. 2020; 587(7834): 466-471.

[12] Li N, Zhou H, Wu H, et al. STING-IRF3 contributes to lipopolysaccharide-induced cardiac dysfunction, inflammation, apoptosis and pyroptosis by activating NLRP3. Redox Biol. 2019; 24:101215.

[13] Liu H, Hu Q, Ren K, et al. ALDH2 mitigates LPS-induced cardiac dysfunction, inflammation, and apoptosis through the cGAS/STING pathway. Mol Med. 2023; 29(1): 171.

[14] Yamaguchi Y, Yamamoto H, Tobashima K. Versican—a critical extracellular matrix regulator of immunity and inflammation. Front Immunol. 2020; 11: 512.

[15] Dong H, Du T, Premaratne S, et al. Relationship between Adamts4 and carotid atherosclerotic plaque vulnerability in humans. J Vasc Surg. 2018; 67(4): 1120-1126.

[16] Kim JY, Choi HS, Kim MJ. TGF-β signaling in fibroblast activation and fibrosis: lessons from idiopathic pulmonary fibrosis. Signal Transduct Target Ther. 2021; 6(1): 1-16.

[17] Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998; 93(7): 1159-1170.

[18] Xia Y, Dobaczewski M, Gonzalez-Quesada C, et al. Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension. 2011; 58(5): 902-911.

[19] Belmadani S, Bernal J, Wei CC, et al. A thrombospondin-1 antagonist of transforming growth factor-beta activation blocks cardiomyopathy in rats with diabetes and elevated angiotensin II. Am J Pathol. 2007; 171(3): 777-789.

[20] Xie Y, Zhang J, Jin W, et al. Role of Thrombospondin-1 in sepsis-induced myocardial injury. Mol Med Rep. 2021; 24(6): 869.

[21] Taraboletti G, Morbidelli L, Donnini S, et al. The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells. FASEB J. 2000; 14(12): 1674-1676.

[22] Lee NV, Sato M, Annis DS, et al. ADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2. EMBO J. 2006; 25(22): 5270-5283.

[23] Kessler T, Zhang L, Liu Z, et al. ADAMTS-7 inhibits re-endothelialization of injured arteries and promotes vascular remodeling through cleavage of thrombospondin-1. Circulation. 2015; 131(13): 1191-1201.

[24] Seif K, Alidzanovic L, Tischler B, et al. Neutrophil-mediated proteolysis of thrombospondin-1 promotes platelet adhesion and string formation. Thromb Haemost. 2018; 118(12): 2074-2085.

[25] Vistnes M, Erusappan PM, Sasi A, et al. Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction. Cardiovasc Res. 2023; 119(10): 1915-1927.

[26] White ES, Baralle FE, Muro AF. Role of the EDA-fibronectin splice variant in fibrosis. J Cell Sci. 2018; 131(5):e0501.

[27] Johansen AKZ, Kasam RK, Vagnozzi RJ, et al. Transcription factor 21 regulates cardiac myofibroblast formation and fibrosis. Circ Res. 2025; 136(1): 44-58.

[28] Vasudevan SO, Behl B, Rathinam VA, et al. Pyroptosis-induced inflammation and tissue damage. Semin Immunol. 2023; 69:101781.

[29] Snider P, Standley KN, Wang J, et al. Origin of cardiac fibroblasts and the role of periostin. Circ Res. 2009; 105(10): 934-947.

[30] Haywood NJ, Wolny M, Rogers B, et al. Hypertrophic cardiomyopathy mutations in the calponin-homology domain of ACTN2 affect actin binding and cardiomyocyte Z-disc incorporation. Biochem J. 2016; 473(16): 2485-2493.

[31] Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 2000; 11(1-2): 59-69.

[32] Sun Y, Yao X, Zhang QJ, et al. Beclin-1-dependent autophagy protects the heart during sepsis. Circulation. 2018; 138(20): 2247-2262.

[33] Camelliti P, Borg TK, Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res. 2005; 65(1): 40-51.

[34] Ma ZG, Yuan YP, Wu HM, et al. Cardiac fibrosis: new insights into the pathogenesis. Int J Biol Sci. 2018; 14(12): 1645-1657.

[35] Amrute JM, Luo X, Penna V, et al. Targeting immune-fibroblast cell communication in heart failure. Nature. 2024; 635(8038): 423-433.

[36] Ma Z, Mao C, Chen X, et al. Peptide vaccine against ADAMTS-7 ameliorates atherosclerosis and postinjury neointima hyperplasia. Circulation. 2023; 147(9): 728-742.

[37] Barallobre-Barreiro J, Radovits T, et al. Extracellular matrix in heart failure: role of ADAMTS5 in proteoglycan remodeling. Circulation. 2021; 144(25): 2021-2034.

[38] Mead TJ, Apte SS. ADAMTS proteins in human disorders. Matrix Biol. 2018; 71-72: 225-239.

[39] Binder MJ, McCoombe S, Williams ED, et al. The extracellular matrix in cancer progression: role of hyalectan proteoglycans and ADAMTS enzymes. Cancer Lett. 2017; 385: 55-64.

[40] Rose KWJ, Taye N, Karoulias SZ, et al. Regulation of ADAMTS proteases. Front Mol Biosci. 2021; 8:701959.

[41] Omura J, Satoh K, Kikuchi N, et al. ADAMTS8 promotes the development of pulmonary arterial hypertension and right ventricular failure: a possible novel therapeutic target. Circ Res. 2019; 125(10): 884-906.

[42] Wang X, Chen W, Zhang J, et al. Critical role of ADAMTS2 (A Disintegrin and Metalloproteinase With Thrombospondin Motifs 2) in cardiac Hypertrophy induced by pressure overload. Hypertension. 2017; 69(6): 1060-1069.

[43] Acharya A, Baek ST, Huang G, et al. The bHLH transcription factor Tcf21 is required for lineage-specific EMT of cardiac fibroblast progenitors. Development. 2012; 139(12): 2139-2149.

[44] Fu X, Liu Q, Li C, et al. Cardiac fibrosis and cardiac fibroblast lineage-tracing: recent advances. Front Physiol. 2020; 11: 416.

[45] Kanisicak O, Khalil H, Ivey MJ, et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat Commun. 2016; 7:12260.

[46] Yao Y, Hu C, Song Q, et al. ADAMTS16 activates latent TGF-β, accentuating fibrosis and dysfunction of the pressure-overloaded heart. Cardiovasc Res. 2020; 116(5): 956-969.

[47] Santamaria S, Yamamoto K, Teraz-Orosz A, et al. Exosites in hypervariable Loops of ADAMTS spacer domains control substrate recognition and proteolysis. Sci Rep. 2019; 9(1):10914.

[48] Flannery CR, Zeng W, Corcoran C, Collins-Racie LA, et al. Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J Biol Chem. 2002; 277(45): 42775-42780.

[49] Gao W, Anderson PJ, Sadler JE. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood. 2008; 112(5): 1713-1719.

[50] Ma ZG, Yuan YP, Fan D, et al. IRX2 regulates angiotensin II-induced cardiac fibrosis by transcriptionally activating EGR1 in male mice. Nat Commun. 2023; 14(1): 4967.

Rights & permissions

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.